Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Home · Cities
City Coverage Index

Semaglutide by City

Top 30 U.S. metros + DC.

30 metros + DCUpdated 2026-05-08
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

All 30 metros + DC

Atlanta (GA) Austin (TX) Baltimore (MD) Boston (MA) Charlotte (NC) Chicago (IL) Columbus (OH) Dallas (TX) Denver (CO) Detroit (MI) Fort Worth (TX) Houston (TX) Indianapolis (IN) Jacksonville (FL) Las Vegas (NV) Los Angeles (CA) Memphis (TN) Miami (FL) Milwaukee (WI) Nashville (TN) New York City (NY) Oklahoma City (OK) Philadelphia (PA) Phoenix (AZ) Portland (OR) San Antonio (TX) San Diego (CA) San Francisco (CA) San Jose (CA) Seattle (WA) Washington, DC (DC)

New cities (May 2026)

Important medical and regulatory disclosure: Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.